Group Challenges Proposed Limits on Vial Labeling - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Group Challenges Proposed Limits on Vial Labeling


ePT--the Electronic Newsletter of Pharmaceutical Technology

In late May 2010, the Consortium for the Advancement of Patient Safety (CAPS) told a meeting of the US Pharmacopeia’s (USP’s) Nomenclature Expert Committee that the latter’s proposal to restrict printing on ferrules and cap overseals was ambiguous and could unintentionally reduce patient safety. CAPS’s comments were based on a three-part study that the group commissioned to evaluate USP’s proposed revision of USP General Chapter <1>, “Injections, Labeling on Ferrules and Cap Overseals,” which is scheduled to become effective in May 2011.
 
USP had held that healthcare professionals should rely exclusively on package inserts and vial labels for information about drug products. The organization proposed limiting cap messages to a small set of drugs that pose a risk of imminent harm or death in the event of medication errors. In 2009, a representative of the US Food and Drug Administration recommended that a human-factors engineering study be conducted to provide data to evaluate USP’s proposal.
 
CAPS hired Anthony Andre, founding principal of Interface Analysis Associates and adjunct professor of human factors and ergonomics at San Jose State University, to study the relationship between patient safety and messages on ferrule and cap overseals. The resulting three-phase study includes a literature review; an online survey of healthcare practitioners, which was conducted in December 2009; and a human-factors research study, in which healthcare practitioners participated in March 2010.
 
Andre’s literature review did not find any reported incidents of medication errors that were associated with cap messages. In addition, the human-factors principles found in scientific literature did not support the premises of USP’s proposal.
 
The majority of respondents to the online survey of healthcare practitioners said that the USP proposal would prohibit important cap messages. About 80% of respondents predicted that medication errors would increase if many of the currently allowed cap messages were prohibited. Roughly 69% of respondents disagreed with USP’s approach to making warnings more prominent for healthcare professionals.
 
Participants in the empirical human-factors study had to select the correct drug from a group of drug vials, some of which had cap labels that would be prohibited by the USP proposal, and some of which did not. Participants selected drugs with cap labels more accurately and more quickly than they selected unlabeled drugs, according to the report. Participants rated the labeled drugs as easy to use more often than the unlabeled drugs. The 20 participants included nurses, physicians, and pharmacists who normally handle drug vials and check drugs against prescriptions.
 
“The science of human factors, coupled with our recent research, shows that the cap area is an underutilized and highly visible area of the drug vial that is well-suited to present key medication and warning information toward aiding healthcare practitioners in selecting the correct drug in the correct concentration and dose,” said Andre in a CAPS press release.
  

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here